Levin Josh, Chan John, Huynh Lisa, Smuck Matt, Koltsov Jayme, Kesikburun Bilge, Wagner Graham E, Caragea Marc, Kuo Keith, McCormick Zachary L, Schneider Byron, Berlin Evan, Kennedy D J, Kesikburun Serdar
Department of Orthopaedic Surgery, Stanford University, 450 Broadway St., Pavilion C; 4th Floor, MC 6342, Redwood City, CA, 94063, USA.
Department of Neurosurgery, Stanford University, USA.
Interv Pain Med. 2021 Dec 16;1(1):100004. doi: 10.1016/j.inpm.2021.100004. eCollection 2022 Mar.
Thoracic transforaminal epidural steroid injections (TFESIs) are procedures performed for the treatment of thoracic spine pain (TSP). The literature on these interventions is sparse.
To report outcomes of thoracic TFESIs for TSP indications.
Multicenter, retrospective, cross-sectional cohort study.
Consecutive patients receiving thoracic TFESIs at three academic spine centers.
The primary outcome was the proportion of patients reporting at least 50% improvement in NRS pain score at short-term follow-up (>1 week, <3 months post-injection).
A chart review was performed of consecutive patients who underwent a thoracic TFESI over a 4- to 10-year time period at three academic spine centers and had reported an NRS pain score at short-term follow-up.
Overall, 19/64 patients (30% [95% CI 20-42%]) experienced ≥50% relief following the injection at a median 22 days follow-up. 42% [95% CI 31-54%] experienced at least a 2-point improvement in NRS score. There was a slight improvement in median NRS scores from pre-to post-procedure of -1 (IQR -3, 0), from 6/10 to 5/10 (p < 0.001). The success rate (≥50% pain relief) was 36% [95%CI 22-52%] in those with a disc herniation as compared to 21% [95%CI 10-40%]) in those with degenerative stenosis; however, the difference did not reach statistical significance. There was a trend towards a greater success rate in those who were employed vs. unemployed (43% [95% CI 27-61%] vs. 19% [95% CI 9-36%]).
This is the largest series reporting outcomes from thoracic TFESI to date. Overall, the observed success rate was low compared to known success rates associated with TFESI for the treatment of pain at cervical and lumbar spinal regions.
胸椎经椎间孔硬膜外类固醇注射(TFESI)是用于治疗胸椎疼痛(TSP)的操作。关于这些干预措施的文献稀少。
报告胸椎TFESI治疗TSP适应症的结果。
多中心、回顾性、横断面队列研究。
在三个学术性脊柱中心接受胸椎TFESI的连续患者。
主要观察指标是在短期随访(注射后>1周,<3个月)时报告数字评分量表(NRS)疼痛评分改善至少50%的患者比例。
对在三个学术性脊柱中心4至10年期间接受胸椎TFESI且在短期随访中报告了NRS疼痛评分的连续患者进行病历审查。
总体而言,19/64例患者(30%[95%CI 20 - 42%])在中位22天随访时注射后疼痛缓解≥50%。42%[95%CI 31 - 54%]的患者NRS评分至少提高2分。术前至术后NRS评分中位数有轻微改善,从6/10降至5/10,下降1分(四分位间距为-3, 0)(p < 0.001)。椎间盘突出患者的成功率(疼痛缓解≥50%)为36%[95%CI 22 - 52%],而退行性狭窄患者为21%[95%CI 10 - 40%];然而,差异无统计学意义。就业患者与失业患者相比有更高成功率的趋势(43%[95%CI 27 - 61%]对19%[95%CI 9 - 36%])。
这是迄今为止报告胸椎TFESI结果的最大系列研究。总体而言,与已知的颈椎和腰椎区域TFESI治疗疼痛的成功率相比,观察到的成功率较低。